Awarded for year-on-year outstanding international trade performance.
Second Queen’s Award for Enterprise following previous award in 2014 in recognition of substantial growth and commercial success


PRESS RELEASE

London, UK – 23 April 2019: Ergomed plc, (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, today announces that PrimeVigilance, its pharmacovigilance, regulatory and medical information service provider, has been awarded the Queen’s Award for Enterprise for the second time reinforcing PrimeVigilance’s broad leadership position as a provider of contract pharmacovigilance, regulatory and medical information services. Now in its 53rd year, the Queen’s Awards for Enterprise are seen as the most prestigious business awards in the country.

PrimeVigilance has received the 2019 Queen’s Award for International Trade in recognition of its year-on-year outstanding services to a pharmaceutical, biotechnology and medical device companies across its global customer base. As an International Trade winner, PrimeVigilance has demonstrated substantial growth in overseas markets and commercial success, further cementing its place as a global leader in pharmacovigilance and the collection of Real World Evidence data.

PrimeVigilance first received a Queen’s Award for Enterprise in 2014 in recognition of its substantial growth and commercial success and this second award recognizes the outstanding contribution played by the dedicated professionals that partner with and support PrimeVigilance’s clients.

In addition to pharmacovigilance, Ergomed provides full CRO services across all phases of clinical development and therapeutic areas under the Ergomed brand, with a particular focus on orphan drug development.

The global pharmacovigilance market is forecast to grow to more than $8 billion by 2024 from around $3 billion in 2015, with contract outsourcing forecast to expand from around 30% of the market in 2015 to approximately 50% in 2024. (Source: Global Market Insights 2017.)

Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: “We are delighted that Ergomed’s PrimeVigilance has been honoured with a Queen’s Award for the second time in recent years. This prestigious accolade recognises the Company’s continued year-on-year international growth and reinforces Ergomed’s position as a leading provider of services to the pharmaceutical industry, but more importantly it is testament to our excellent people and their valuable contribution towards improving the lives of patients.

Dr Jan Petráček, Chief Executive Officer of PrimeVigilance, commented: “We are excited at being awarded this prestigious award again. It reflects the excellent teams here at Ergomed’s PrimeVigilance. The vital work performed by our professionals in support of the pharmaceutical industries is really helping to improve patient’s safety and outcomes and it is this professionalism that drives our continuous development. Every day in every way we are getting better and better.”

Enquiries:

Ergomed plc : Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman, Ergomed plc )
Roy Ovel (Chief Commercial Officer, Ergomed plc)
Jan Petráček (Chief Executive Officer, PrimeVigilance)

About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com and https://www.primevigilance.com.

For more information, please contact:
marketing@primevigilance.com